Predictive Oncology (POAI) reported Q1 2024 EPS of ($1.04), negative ROE of 104.21%, and a negative net margin of 785.
Predictive Oncology (NASDAQ:POAI) reported Q1 2024 earnings of ($1.04) EPS, with negative ROE at 104.21% and a negative net margin of 785.62%. The company generated $0.42M in revenue. Shares traded down $0.02 to $1.72, with a market cap of $6.98M, P/E ratio of -0.50 and beta of 1.39. Predictive Oncology Inc is a science-driven company focused on oncology drug discovery, providing various solutions for the industry.
May 15, 2024
4 Articles